During the past decade, Kalamazoo Hematology and Oncology conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kalamazoo Hematology and Oncology" #1 sponsor was "Millennium Pharmaceuticals, Inc." with 2 trials, followed by "ARCA Biopharma, Inc." with 1 trials sponsored, "Agennix" with 1 trials sponsored, "Celgene" with 1 trials sponsored and "Celgene Corporation" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kalamazoo Hematology and Oncology" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "Cephalon" with 1 trials as a collaborator, "Instituto Grifols, S.A." with 1 trials as a collaborator, "Memorial Sloan Kettering Cancer Center" with 1 trials as a collaborator and "Prologue Research International" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Kalamazoo Hematology and Oncology" are "Catheter Occlusion" (1 trials), "Diffuse Large B-cell Lymphoma" (1 trials), "Extensive-stage Small Cell Lung Cancer" (1 trials), "Idiopathic Thrombocytopenic Purpura" (1 trials) and "Lung Cancer" (1 trials). Many other conditions were trialed in "Kalamazoo Hematology and Oncology" in a lesser frequency.

Most popular intervention types in "Kalamazoo Hematology and Oncology" are "Drug" (11 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Alfimeprase" (1 trials), "Amrubicin" (1 trials), "Bevacizumab" (1 trials), "Bortezomib" (1 trials) and "CC-5013 (lenalidomide)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kalamazoo Hematology and Oncology" are 11 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Kalamazoo Hematology and Oncology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Kalamazoo Hematology and Oncology, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Kalamazoo Hematology and Oncology, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".